Zila settles class action lawsuits
This article was originally published in Clinica
Zila has settled a series of class action lawsuits dating from early 1999, although it maintains it would have ultimately prevailed in the litigation. The lawsuits were filed after an FDA advisory panel did not recommend the company's OraTest oral cancer test and asked for further information. The test is approved more than a dozen countries.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.